Mainz Biomed (MYNZ) Liabilities and Shareholders Equity (2020 - 2025)
Historic Liabilities and Shareholders Equity for Mainz Biomed (MYNZ) over the last 6 years, with Q2 2025 value amounting to $9.8 million.
- Mainz Biomed's Liabilities and Shareholders Equity rose 1596.26% to $9.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $46.9 million, marking a year-over-year decrease of 2320.14%. This contributed to the annual value of $13.2 million for FY2024, which is 1408.82% down from last year.
- As of Q2 2025, Mainz Biomed's Liabilities and Shareholders Equity stood at $9.8 million, which was up 1596.26% from $13.2 million recorded in Q4 2024.
- In the past 5 years, Mainz Biomed's Liabilities and Shareholders Equity ranged from a high of $27.6 million in Q2 2022 and a low of $8.5 million during Q2 2024
- For the 5-year period, Mainz Biomed's Liabilities and Shareholders Equity averaged around $16.2 million, with its median value being $16.7 million (2023).
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 139134.75% in 2021, then plummeted by 5620.83% in 2024.
- Over the past 5 years, Mainz Biomed's Liabilities and Shareholders Equity (Quarter) stood at $10.0 million in 2021, then surged by 101.59% to $20.2 million in 2022, then decreased by 23.87% to $15.4 million in 2023, then fell by 14.09% to $13.2 million in 2024, then decreased by 25.95% to $9.8 million in 2025.
- Its last three reported values are $9.8 million in Q2 2025, $13.2 million for Q4 2024, and $8.5 million during Q2 2024.